NCT07282821
Bempedoic Acid Therapy for Polycystic Kidney Disease
Phase 2, NOT_YET_RECRUITING
Intervention: Bempedoic acid vs placebo
New non-V2 pharmacologic disease-modifying signal; no efficacy data yet
View on ClinicalTrials.govADPKD clinical trials worth watching right now
These are registry-backed tracked programs. Active does not mean effective, and early-phase does not mean practice-ready.
NCT07454174
Metabolic Impacts of Ren-Nu dietary program for PKD
Pilot (NA), RECRUITING
Intervention: Ren-Nu ketogenic program + KetoCitra
Lifestyle/metabolic pilot signal; not proof of disease modification
View on ClinicalTrials.govNCT07280585
STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease
Phase 3, RECRUITING
Intervention: Dapagliflozin 10 mg vs placebo
Large pivotal non-V2 trial; no efficacy outcomes yet and KDIGO currently does not recommend SGLT2i specifically for ADPKD progression slowing outside evidence generation
View on ClinicalTrials.govNCT04939935
IMPEDE-PKD: Metformin therapy to ease decline of kidney function in ADPKD
Phase 3, RECRUITING
Intervention: Metformin XR vs control
Large confirmatory trial in progress; KDIGO currently recommends against metformin specifically for ADPKD progression in non-diabetes
View on ClinicalTrials.govNCT06582875
Glucagon-Like Peptide-1 Receptor Agonist in ADPKD
Phase 2, RECRUITING
Intervention: Tirzepatide vs placebo
Metabolic/weight pathway disease-modification hypothesis under test; renal hard-outcome evidence not yet available
View on ClinicalTrials.govNCT06289998
Study of Tamibarotene in Patients With ADPKD
Phase 2, ACTIVE_NOT_RECRUITING
Intervention: Tamibarotene vs placebo
Retinoid-pathway candidate with imaging endpoint focus; no posted efficacy results yet
View on ClinicalTrials.govHow to read trial pages without over-reading them
- Recruiting does not mean effective.
- Phase movement does not equal meaningful kidney benefit.
- Registry status is useful for tracking, not proof of efficacy.